<H1> Leaders in Pharmaceutical Business Intelligence (LPBI) Group </H1> |
<H1> https://reinvent.awsevents.com/ </H1> |
<H1> </H1> |
<H1> AWS re:Invent 2020 – Life Sciences Attendee Guide </H1> |
<H1> </H1> |
<H1> Healthcare Attendee Guide </H1> |
<H2> Funding, Deals & Partnerships: BIOLOGICS & MEDICAL DEVICES; BioMed e-Series; Medicine and Life Sciences Scientific Journal – http://PharmaceuticalIntelligence.com </H2> |
<H2> Life-changing surgical blade technology to enhance patient healing </H2> |
<H2> Two Site Map Proposals for LPBI’s New Web Site </H2> |
<H2> @@@@@ </H2> |
<H2> @@@@ </H2> |
<H2> COVID-19 T-cell immune response map, immunoSEQ T-MAP COVID for research of T-cell response to SARS-CoV-2 infection </H2> |
<H2> Watch the video </H2> |
<H2> </H2> |
<H2> End-to-end solution; from experimental design to publication ready data </H2> |
<H2> Nanoparticles can turn off genes in bone marrow cells </H2> |
<H2> The complication of Pfizer’s Vaccine Distribution’s Plan </H2> |
<H2> Regeneron’s new antibody cocktail drug, REGN-COV2 </H2> |
<H2> McKinsey experts on COVID-19: Implications for business: Executive Briefing </H2> |
<H2> Leveraging Clinical Narrative Text at Scale: Applying Natural Language Processing to Understand the Patient Care Experience @NIH.gov </H2> |
<H2> View Webinar </H2> |
<H2> Purpose </H2> |
<H2> Presenters </H2> |
<H2> re:Invent 2020 – Virtual 3 weeks Conference, Nov. 30 – Dec. 18, 2020: How Healthcare & Life Sciences leaders are using AWS to transform their businesses and innovate on behalf of their customers. </H2> |
<H2> https://virtual.awsevents.com/agenda </H2> |
<H2> Design your re:Invent experience </H2> |
<H2> </H2> |
<H2> Life Sciences at re:Invent 2020 </H2> |
<H2> Dates and Presentation title </H2> |
<H2> BlockChain Architecture </H2> |
<H2> Life Science and Healthcare </H2> |
<H2> </H2> |
<H2> </H2> |
<H2> Life Sciences sessions </H2> |
<H2> Healthcare at re:Invent 2020 </H2> |
<H2> Healthcare sessions </H2> |
<H2> Data Architecture for Blockchain Deployment of Digital Assets: LPBI IP Asset Classes I,II,III </H2> |
<H2> A. 1.0 LPBI – 2012–2020 – IP Assets available for sale </H2> |
<H2> B. 2.0 LPBI – 2021–2025 – </H2> |
<H2> IP Assets under construction – </H2> |
<H2> WILL BE AVAILABLE FOR SALE </H2> |
<H2> Data Architecture Questions </H2> |
<H2> </H2> |
<H2> For 2.0 LPBI Products </H2> |
<H2> </H2> |
<H2> Follow Blog via Email </H2> |
<H2> Recent Posts </H2> |
<H2> Archives </H2> |
<H2> Categories </H2> |
<H2> meta </H2> |
<H2> </H2> |
<H3> Life-changing surgical blade technology to enhance patient healing </H3> |
<H3> Two Site Map Proposals for LPBI’s New Web Site </H3> |
<H3> </H3> |
<H3> </H3> |
<H3> Site Map Version 1: Proposal by Aviva </H3> |
<H3> 2021-2025: 2.0 LPBI SITE MAP </H3> |
<H3> PRODUCTS, 2021 – 2025 </H3> |
<H3> 2012-2020: 2.0 LPBI SITE MAP </H3> |
<H3> Site Map Version 2: Proposal by Gail S. Thornton </H3> |
<H3> Leaders in Pharmaceutical Business Intelligence Group </H3> |
<H3> Our Company Our Services </H3> |
<H3> Our Commitment </H3> |
<H3> COVID-19 T-cell immune response map, immunoSEQ T-MAP COVID for research of T-cell response to SARS-CoV-2 infection </H3> |
<H3> T cells are the adaptive immune system’s first responders to any virus, circulating in the blood to detect and quickly multiply to attack the virus, often before symptoms appear. Adaptive Biotechnologies’ unique MIRA Technology and immunoSEQ Technology has enabled us to create a comprehensive view of the T-cell response to SARS-CoV-2 infection. This data has been made public as part of the ImmuneCODE Initiative in order to help propel drug, vaccine, and clinical trial research. We are launching immunoSEQ T-MAP COVID with the tools to study and analyze the COVID-19 T-cell immune response map. </H3> |
<H3> Ready to learn more about how our immunoSEQ T-MAP COVID service can help you propel your research forward? Contact us below to speak with one of our experts. </H3> |
<H3> Nanoparticles can turn off genes in bone marrow cells </H3> |
<H3> The complication of Pfizer’s Vaccine Distribution’s Plan </H3> |
<H3> </H3> |
<H3> Regeneron’s new antibody cocktail drug, REGN-COV2 </H3> |
<H3> McKinsey experts on COVID-19: Implications for business </H3> |
<H3> Leveraging Clinical Narrative Text at Scale: Applying Natural Language Processing to Understand the Patient Care Experience @NIH.gov </H3> |
<H3> Leveraging Clinical Narrative Text at Scale </H3> |
<H3> Intended Audience </H3> |
<H3> re:Invent 2020 – Virtual 3 weeks Conference, Nov. 30 – Dec. 18, 2020: How Healthcare & Life Sciences leaders are using AWS to transform their businesses and innovate on behalf of their customers. </H3> |
<H3> Marketplace </H3> |
<H3> </H3> |
<H3> </H3> |
<H3> Natural Language Processing </H3> |
<H3> BLOCKCHAIN </H3> |
<H3> </H3> |
<H3> </H3> |
<H3> Kelli Jonakin, Ph.D. </H3> |
<H3> David Niewolny </H3> |
<H3> Data Architecture for Blockchain Deployment of Digital Assets: LPBI IP Asset Classes I,II,III </H3> |
<H3> Distinction between A and B, below </H3> |
<H3> A. 1.0 LPBI – 2012–2020 – IP Assets available for sale </H3> |
<H3> B. 2.0 LPBI – 2021–2025 – IP Assets under construction – WILL BE AVAILABLE FOR SALE </H3> |
<H3> A.1 A List of Scientific articles N=6,000 </H3> |
<H3> STORED in Excel file run on 6/30/2020 and 12/31/2020 </H3> |
<H3> A.2 A List of 16 e-BOOKS </H3> |
<H3> </H3> |
<H3> A.3 A List of e-Proceedings and Tweet Collections </H3> |
<H3> B.1 Journal articles </H3> |
<H3> B.2 16 e-Books </H3> |
<H3> B.3 eProceedings & Tweet collections </H3> |
<H3> Bundles of Insights for Targeted Industries – B–to-B </H3> |
<H3> Bundles of insights for theScientific Community – B–to-C </H3> |
Social
Social Data
Cost and overhead previously rendered this semi-public form of communication unfeasible.
But advances in social networking technology from 2004-2010 has made broader concepts of sharing possible.